What are the proposed mechanisms by which guselkumab could potentially lead to posterior reversible encephalopathy syndrome (PRES)?
Abstract
No direct evidence links guselkumab to PRES, but possible mechanisms may involve modulation of the immune system and endothelial function due to IL-23 inhibition.
Fields of Study & Subjects
Neurological Complications and Syndromes
Vasculitis and related conditions
Cerebral Venous Sinus Thrombosis
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 28 January 2026